FDA Approves Expansion for BMS' Reblozyl as First-Line Anemia Treatment

Published on: 

The drug is now indicated for adults with low-risk myelodysplastic syndromes.

Bristol Myers Squibb disclosed that the FDA has approved Reblozyl (luspatercept-aamt) for the treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions. Expansion to the first-line setting was based on positive results from phase three trials.

Advertisement

“Today's expanded approval of Reblozyl marks an important milestone in our commitment to MDS patients with anemia by providing a durable and more effective treatment option, with more convenient and less frequent administration,” said Wendy Short-Bartie, SVP, general manager, US hematology and cell therapy, Bristol Myers Squibb, in a company press release. “We remain dedicated to addressing hard-to-treat diseases with significant burden to patients and look forward to bringing this important option earlier in the treatment process.”

Reference: U.S. FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions. Bristol Myers Squibb. August 28, 2023. Accessed August 31, 2023. https://news.bms.com/news/corporate-financial/2023/U.S.-FDA-Approves-Bristol-Myers-Squibbs-Reblozyl-luspatercept-aamt-as-First-Line-Treatment-of-Anemia-in-Adults-with-Lower-Risk-Myelodysplastic-Syndromes-MDS-Who-May-Require-Transfusions/default.aspx